KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Esperion Therapeutics (ESPR) Equity Average (2018 - 2025)

Esperion Therapeutics (ESPR) has disclosed Equity Average for 8 consecutive years, with -$376.7 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Equity Average rose 0.74% year-over-year to -$376.7 million, compared with a TTM value of -$376.7 million through Dec 2025, up 0.74%, and an annual FY2025 reading of -$345.3 million, up 18.14% over the prior year.
  • Equity Average was -$376.7 million for Q4 2025 at Esperion Therapeutics, up from -$442.4 million in the prior quarter.
  • Across five years, Equity Average topped out at -$182.8 million in Q1 2021 and bottomed at -$442.4 million in Q3 2025.
  • Average Equity Average over 5 years is -$338.3 million, with a median of -$342.2 million recorded in 2021.
  • The sharpest move saw Equity Average tumbled 1727.85% in 2021, then rose 12.26% in 2024.
  • Year by year, Equity Average stood at -$279.8 million in 2021, then dropped by 10.4% to -$308.9 million in 2022, then plummeted by 39.99% to -$432.5 million in 2023, then rose by 12.26% to -$379.5 million in 2024, then rose by 0.74% to -$376.7 million in 2025.
  • Business Quant data shows Equity Average for ESPR at -$376.7 million in Q4 2025, -$442.4 million in Q3 2025, and -$429.9 million in Q2 2025.